Quadria Capital

What Quadria Capital does

Quadria Capital is a Singapore-headquartered private equity firm founded in 2012 that manages capital exclusively for healthcare investments across South and Southeast Asia. The firm operates under the legal entity Quadria Capital Investment Management Pte Ltd, regulated by the Monetary Authority of Singapore, with additional offices in New Delhi (South Asia hub), Ho Chi Minh City, Jakarta, and a newly opened Dubai office for GCC expansion. The firm manages over US$4.2 billion in assets across multiple funds, with its third fund (Fund III) closed at US$1.07 billion in 2025 — the largest healthcare-focused fundraise in the region per the Singapore Venture & Private Capital Association. The portfolio comprises 29 investments across 8 markets spanning four healthcare verticals: Healthcare Delivery (NephroPlus dialysis network, Maxivision Eye Hospitals, Tam Tri Medical hospitals, AIG Hospitals), Life Sciences (Aragen Life Sciences CRDMO, Encube Ethicals topical drugs, Apex Healthcare pharmaceuticals), Medical Technology (Straits Orthopaedics implants CDMO), and Associated Healthcare Services (MediBuddy digital health, Nobel Hygiene).

Quadria's revenue model is conventional institutional fund management — earning management fees on committed/invested AUM plus carried interest on investment returns above hurdle rates. The firm supplements this with non-traditional capital instruments including a US$200 million social loan (Asia's first, closed in 2023) to fund healthcare, pharmaceutical, and diagnostic investments. Its underlying 'technology' is a proprietary investment methodology rather than software: a healthcare-specific due diligence framework, a defined value creation methodology with dedicated operating partners and a Value Optimisation Board, and a proprietary 3-tiered Impact Management and Measurement Framework (Impact Thesis, ABC Investment Strategy, ESG evaluation process) verified independently by BlueMark and aligned with UN PRI and OPIM principles.

The firm serves a dual customer base: institutional limited partners (sovereign wealth funds, development finance institutions including Proparco, pension funds, family offices) for capital raising, and healthcare companies and entrepreneurs for investment deployment. Go-to-market is relationship-driven and proprietary, leveraging deep local networks for deal origination at favorable valuations, dedicated operational support post-investment, and active portfolio synergies across companies. Recent notable transactions include the US$470 million take-private of Malaysia's Apex Healthcare (2026, largest healthcare buyout in Southeast Asia in five years), the partial IPO exit from NephroPlus (December 2025), and a US$100 million co-investment with Goldman Sachs in Aragen Life Sciences for Indian capacity expansion.

Name

Quadria Capital

Legal name

Quadria Capital Investment Management Pte Ltd

Website

http://quadriacapital.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Quadria Capital is a Singapore-based private equity firm managing over US$4.2 billion in healthcare-focused funds (latest Fund III at US$1.07B) and a 29-company portfolio across South, Southeast Asia, and now the GCC, partnering with healthcare operators to build regional leaders in delivery, life sciences, medtech, and digital health.

Ownership category

akta.pro rank

Product category

Healthcare Private Equity

NAICS

Portfolio Management and Investment Advice (52394), Other Financial Vehicles (525990)

SIC

Investment Advice (6282)

akta.pro primary industry

Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)

akta.pro secondary industry

Endowments (Universities, Foundations, Nonprofits) (FSAAAGAC)

Keywords

• Healthcare private equity
• Growth capital investing
• Fund management services
• Value creation advisory
• Healthcare investment platform

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Private Equity Fund Management: Quadria Capital generates returns by managing private equity funds investing in healthcare companies across South and Southeast Asia. The firm earns management fees on assets under management and performance-based carried interest on investment returns, with a focus on delivering superior financial returns and meaningful social impact. The firm closed Fund III at $1.07 billion.
2. Social Loan Origination: Quadria Capital closed Asia's first social loan of up to $200 million to fund healthcare, pharmaceutical, and diagnostic investments in South and Southeast Asia, aimed at improving access to healthcare and essential services.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

Quadria Capital is a healthcare-focused private equity firm that raises and manages investment funds from institutional investors to acquire and partner with large, scalable healthcare companies across South and Southeast Asia. The firm provides capital, strategic guidance, and operational support through dedicated Operating Partners and a Value Optimisation team to build regional healthcare leaders, generating returns through management fees on assets under management and performance-based carried interest.

Product overview

Quadria Capital is a healthcare-focused private equity firm that operates as a fund manager and investment platform rather than a traditional product company. The firm's offering consists of investment management services and a portfolio of healthcare companies across South and Southeast Asia. The portfolio spans four main sectors: Healthcare Delivery (dialysis networks, eye care hospitals), Life Sciences (pharmaceuticals, CRDMO services, topical drugs), Medical Devices (orthopaedic manufacturing), and Associated Healthcare Services (digital health platforms, hygiene products). Key portfolio companies include NephroPlus (dialysis), Maxivision (eye care), MediBuddy (digital health), Encube Ethicals (topical drugs), Nobel Hygiene (personal hygiene), Apex Healthcare (pharmaceutical distribution), Aragen Life Sciences (contract research/manufacturing), and Straits Orthopaedics (medical devices).

Differentiator

Problem solved

Functional benefit

Brands

• HealthQuad: India's largest growth venture firm focused on investing in new-age, transformative healthcare models, co-founded by Quadria's Managing Partner Abrar Mir
• Quadria Capital Fund III LP

Products and services

• Quadria Capital Fund III LP
• Value Optimisation Services

Quantifiable outcome

• NephroPlus IPO listed at 7% premium over issue price of INR 490, subscribed 14 times overall and 27 times by Qualified Institutional Buyers
• +6 more outcomes

Named customers8 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core.

• BlueMarkcoreOthers · 2 June 2026BlueMark, a specialist verification provider for impact investing, conducted independent assessment of Quadria Capital Fund III's impact management measurement framework and issued verification statements for 2025 and 2026, affirming the effectiveness of Quadria's IMM framework.
• Singapore Venture & Private Capital Association (SVCA)coreOthers · 18 September 2025SVCA awarded Quadria Capital Fundraise of the Year 2025 for raising Fund III at US$1.07 billion, exceeding its $800 million target. The firm also won SVCA's Private Equity Deal of the Year for two consecutive years.
• Straits Orthopaedics (Co-investment with Founder)coreStrategic or Co-development Partner · 28 April 2023Quadria Capital acquired a majority stake in Straits Orthopaedics, a Penang-based medical device manufacturer, from its founder Mr. TH Su and Apex Healthcare Bhd. The deal included re-investments by the founder and Apex Healthcare Bhd., with Mr. Su reappointed as CEO to lead future growth. The partnership aims to strengthen the company's market position as a global orthopaedic manufacturing leader.
• United Nations Principles for Responsible Investment (UN PRI)coreOthersQuadria Capital is a signatory to UN PRI and achieved top ratings in its inaugural assessment. The firm is aligned with all UN PRI principles for responsible investment.
• Operating Principles for Impact Management (OPIM)coreOthersQuadria Capital is a signatory to OPIM, reaffirming alignment with all nine principles. Quadria's Impact Management Framework brings to life its Responsible Investment Policy.
• Aragen Life SciencescoreStrategic or Co-development PartnerQuadria Capital invested $100 million in Aragen Life Sciences for domestic capacity expansion in India. Aragen serves as a trusted R&D and manufacturing partner to the global life sciences industry, servicing over 400 customers across large pharma, biotech, agrochemical, and animal health industries.

Scale indicators15 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• TVM Capital Healthcare: Healthcare-focused private equity firm investing across Asia and the Middle East with dedicated operating partners and a regional value-creation approach. Direct peer to Quadria given overlapping healthcare-only thesis, geographic footprint (MENA + Asia), and similar cheque sizes in growth-stage healthcare.
• Olympus Capital Asia: Asia-focused private equity firm with a strong healthcare and consumer orientation, targeting control and growth investments across India, China, and Southeast Asia. Direct peer to Quadria based on shared regional remit, healthcare sector focus, and growth-equity mandate.
• Everlife Asia Partners: Southeast Asia-focused healthcare distribution and investment platform backed by founding investors including Quadria's co-founder Abrar Mir. Direct peer in the Asia healthcare distribution and specialty investing space with comparable therapeutic and geographic coverage.
• Navis Capital Partners: One of the largest dedicated Southeast Asia-focused private equity firms, investing across healthcare, consumer, and industrials with a strong operating-partner value-creation model. Direct peer based on shared Southeast Asia healthcare exposure and growth-equity approach.
• Creador: Southeast and South Asia-focused private equity firm investing in growth-stage consumer, financial services, and healthcare businesses. Direct peer given overlapping South/Southeast Asia focus, growth-stage mandate, and similar founder-driven value-creation orientation.
• Affirma Capital (formerly Standard Chartered PE): Pan-Asia mid-market private equity firm with sector coverage spanning healthcare, consumer, and business services across India, Southeast Asia, and Greater China. Direct peer given shared Asia growth-equity mandate and comparable fund size.
• AID Partners Capital: Hong Kong-based private equity firm focused on healthcare and consumer investments across Greater China, Southeast Asia, and India. Direct peer based on Asia healthcare sector focus and growth-to-control investment approach.

Broad incumbents

• Baring Private Equity Asia (EQT): Large pan-Asia private equity platform (now part of EQT) with broad sector coverage including significant healthcare exposure. Broader incumbent peer given much larger fund sizes, broader sector mandate, and global LP base, but competes for similar control deals in Asia healthcare.
• KKR Asia Healthcare: Global private equity firm with an established Asia healthcare strategy spanning delivery, pharma services, and medtech. Broader incumbent peer given mega-fund scale, global LP base, and growing competition for control healthcare assets in India and Southeast Asia.
• Asia Healthcare Fund (Advent International): Global private equity firm with dedicated Asia healthcare investing across pharmaceuticals, medtech, and healthcare services. Broader incumbent peer given much larger fund sizes and global operating resources, but comparable in Asian healthcare sector focus and growth-to-control mandate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/2463054
• Xx.com/QuadriaCapital

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries10 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments24 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quadria Capital